An Investigator-initiated Trial Evaluating the Efficacy and Safety of Anti-CD19 Universal CAR-NK(U-CAR-NK) Cells Therapy Combined With Hematopoietic Stem Cell Transplantation(HSCT) for B Cell Hematologic Malignancies
Latest Information Update: 02 Dec 2022
At a glance
- Drugs Anti CD19 universal chimeric antigen receptor natural killer cell therapy Chongqing Precision Biotech (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; B-cell prolymphocytic leukaemia
- Focus Adverse reactions
- 27 Nov 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 13 Oct 2022 New trial record